Status:

COMPLETED

Inactivated Influenza Via Jet Injection

Lead Sponsor:

PharmaJet, Inc.

Conditions:

Influenza, Human

Eligibility:

All Genders

18-64 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to determine if the administration of flu vaccine using Needle-Free is equivalent to Needle and Syringe administration as measured by laboratory tests of immune response.

Detailed Description

Primary: To evaluate the non-inferiority of flu vaccine administered by needle-free intramuscular (IM) injection versus needle and syringe IM injection as determined with serum hemagglutination inhib...

Eligibility Criteria

Inclusion

  • Adults aged ≥ 18 and ≤ 64 years of age at time of enrollment
  • Willing and able to give informed consent after reading the consent form and given adequate opportunity to discuss the study with the investigator or qualified designee
  • Willing and able to adhere to all protocol required study procedures and to attend scheduled visits
  • Able to receive the trivalent influenza vaccine (TIV) or quadrivalent influenza vaccine (QIV) based on PI judgment
  • Stable health status with no exclusionary medical or neuropsychiatric conditions as determined during the screening evaluation and based on the clinical judgment of the investigator or qualified designee
  • Access to a consistent means of telephone contact

Exclusion

  • Presence of any febrile illness (oral temperature \>38 °C) on the day of immunization. Such subjects will be reevaluated for enrollment after resolution of illness
  • Presence of significant acute or chronic uncontrolled medical or neuropsychiatric illness and /or presence of any significant condition that may prohibit inclusion as determined by the investigator or his qualified designee. Uncontrolled is defined as: requiring institution of a new treatment within 1 month prior to study enrollment or change in medication dosage in the month prior to study enrollment
  • Any known immunosuppressive condition including: history of human immunodeficiency virus (HIV) infection, cancer or cancer treatment within 3 years of study enrollment, systemic glucocorticoids (in a dose ≥10 mg prednisone daily or equivalent for more than 7 consecutive days or for 10 or more days in total) within 1 month of study enrollment, or any other cytotoxic or immunosuppressive drug within 3 months of study enrollment. Any significant disorder of coagulation that would increase the risk of intramuscular injections or treatment with Coumadin derivatives or heparin
  • Known or suspected to be allergic to eggs, chicken protein, neomycin, polymyxin or influenza vaccine
  • History of severe or previous serious adverse reaction after an influenza vaccination
  • Receipt of any immunoglobulin and/or blood products within 3 months of immunization or planned administration of any of these products during the study period
  • Prior history of any demyelinating disease including Guillain-Barre syndrome.
  • Presence of an active neurological disorder
  • History of significant alcohol or drug abuse within one year prior to study enrollment
  • Influenza vaccination or laboratory confirmed influenza infection within the previous six months before study vaccination or planned influenza vaccination during the study period
  • Planned administration of any non-influenza vaccines 30 days prior to the study or during the study period
  • Pregnant or plans to become pregnant during the study period
  • Currently enrolled in another vaccine or drug study

Key Trial Info

Start Date :

November 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2015

Estimated Enrollment :

985 Patients enrolled

Trial Details

Trial ID

NCT02290691

Start Date

November 1 2014

End Date

January 1 2015

Last Update

November 30 2017

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Optimal Research LLC

Huntsville, Alabama, United States, 35802

2

Optimal Research, LLC

San Diego, California, United States, 92108

3

Optimal Research, LLC

Melbourne, Florida, United States, 32934

4

Optimal Research, LLC

Peoria, Illinois, United States, 64614